Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunogenicity of a Prime-Boost Vaccine Containing the Circumsporozoite Proteins of Plasmodium vivax in Rodents

Texto completo
Autor(es):
Mostrar menos -
Teixeira, Lais H. [1, 2] ; Tararam, Cibele A. [1, 2] ; Lasaro, Marcio O. [3] ; Camacho, Ariane G. A. [1, 2] ; Ersching, Jonatan [1, 2] ; Leal, Monica T. [2, 1] ; Herrera, Socrates [4] ; Bruna-Romero, Oscar [5] ; Soares, Irene S. [6] ; Nussenzweig, Ruth S. [7] ; Ertl, Hildegund C. J. [3] ; Nussenzweig, Victor [7] ; Rodrigues, Mauricio M. [1, 2]
Número total de Autores: 13
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Ctr Terapia Celular & Mol CTCMol, Sao Paulo - Brazil
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 - USA
[4] Malaria Vaccine & Drug Dev Ctr, Cali - Colombia
[5] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Florianopolis, SC - Brazil
[6] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo - Brazil
[7] NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY - USA
Número total de Afiliações: 7
Tipo de documento: Artigo Científico
Fonte: Infection and Immunity; v. 82, n. 2, p. 793-807, FEB 2014.
Citações Web of Science: 13
Resumo

Plasmodium vivax is the most widespread and the second most prevalent malaria-causing species in the world. Current measures used to control the transmission of this disease would benefit from the development of an efficacious vaccine. In the case of the deadly parasite P. falciparum, the recombinant RTS,S vaccine containing the circumsporozoite antigen (CSP) consistently protects 30 to 50% of human volunteers against infection and is undergoing phase III clinical trials in Africa with similar efficacy. These findings encouraged us to develop a P. vivax vaccine containing the three circulating allelic forms of P. vivax CSP. Toward this goal, we generated three recombinant bacterial proteins representing the CSP alleles, as well as a hybrid polypeptide called PvCSP-All-CSP-epitopes. This hybrid contains the conserved N and C termini of P. vivax CSP and the three variant repeat domains in tandem. We also generated simian and human recombinant replication-defective adenovirus vectors expressing PvCSP-All-CSP-epitopes. Mice immunized with the mixture of recombinant proteins in a formulation containing the adjuvant poly(I.C) developed high and long-lasting serum IgG titers comparable to those elicited by proteins emulsified in complete Freund's adjuvant. Antibody titers were similar in mice immunized with homologous (protein-protein) and heterologous (adenovirus- protein) vaccine regimens. The antibodies recognized the three allelic forms of CSP, reacted to the repeated and nonrepeated regions of CSP, and recognized sporozoites expressing the alleles VK210 and VK247. The vaccine formulations described in this work should be useful for the further development of an anti-P. vivax vaccine. (AU)

Processo FAPESP: 12/13032-5 - Geração e análise da imunogenicidade de proteínas recombinantes baseadas nas diferentes formas alélicas do antígeno circumsporozoíta de Plasmodium vivax visando o desenvolvimento de uma vacina universal contra malária
Beneficiário:Irene da Silva Soares
Linha de fomento: Auxílio à Pesquisa - Temático